Bio-Gene Technology (ASX:BGT) announced financial results for the quarter ended 30 September 2022.
Bio-Gene/commercial partners programs advancing through development.
Advancement of other commercial programs with new potential commercial partners.
Regulatory authorities in key markets now engaged on registration pathways with potential for early submissions.
Manufacturing improvements leading to assurance on commercial manufacturing viability.
Patent application submitted in Australia for Qcide use for winged insect control.
Following the announcement the company?s share price fell 4.000%.